Astrazeneca (AZN) Retained Earnings (2009 - 2026)

Astrazeneca's Retained Earnings history runs 18 years deep, the most recent figure standing at $9.7 billion for Q1 2026.

• In Q1 2026, Retained Earnings rose 187.51% year-over-year to $9.7 billion; the TTM figure through Mar 2026 stood at $9.7 billion (up 187.51% YoY), while the FY2025 annual figure was $11.0 billion, up 247.22% from the prior year.
• Retained Earnings was $9.7 billion for Q1 2026 at Astrazeneca, down from $11.0 billion in the prior quarter.
• In the past five years, Retained Earnings ranged from a high of $11.0 billion in Q4 2025 to a low of -$2.5 billion in Q3 2022.
• Historically, Retained Earnings has averaged $1.4 billion across 5 years, with a median of $40.0 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Retained Earnings sank 212.32% in 2022, then soared 1686.79% in 2025.
• A 5-year view of Retained Earnings shows it stood at -$574.0 million in 2022, then jumped by 361.67% to $1.5 billion in 2023, then soared by 110.39% to $3.2 billion in 2024, then soared by 247.22% to $11.0 billion in 2025, then fell by 11.85% to $9.7 billion in 2026.
• The last three Retained Earnings figures came in at $9.7 billion (Q1 2026), $11.0 billion (Q4 2025), and $40.0 million (Q3 2025), per Business Quant data.